Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Indications -- Psoriasis/Chronic Inflammation -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (483)	2/7/2004 11:53:01 AM
From: scaram(o)uche	Respond to of 631

[ excerpt from today's Amgen release ] Patients withdrawn from ENBREL treatment did not have serious adverse events due to psoriasis including disease flares, hospitalizations or transformation of psoriasis to a more severe form of the disease. After discontinuing ENBREL, the median time to relapse (loss of half of PASI improvement achieved while on ENBREL) was approximately three months. After patients relapsed, they were retreated with the same dose they had received at the end of the double-blind period of the study. Overall PASI 75 response rates at both week 12 and 24 of re-treatment (n=297 and n=174, respectively) were similar to those seen after initial treatment in all groups. "Psoriasis is a chronic condition and patients must sometimes stop treatment due to life circumstances such as pregnancy or surgery," said Alice Gottlieb, M.D., Ph.D., director of the Clinical Research Center at University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School. "These data show that ENBREL was stopped and restarted without severe side effects due to psoriasis or loss of efficacy." (excerpted)